Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sai Parenteral'sNSE:SAIPARENT +5.28%14 Return-on-Tangible-Equity is 48.59% as of Sep. 2025, which is 175% above its 10-year median of 17.69. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 897 Drug Manufacturers companies, Sai Parenteral's ranks better than 82.61% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sai Parenteral's's annualized net income for the quarter that ended in Sep. 2025 was ₹33 Mil. Sai Parenteral's's average shareholder tangible equity for the quarter that ended in Sep. 2025 was ₹68 Mil. Therefore, Sai Parenteral's's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was 48.59%.
The historical rank and industry rank for Sai Parenteral's's Return-on-Tangible-Equity or its related term are showing as below:
NSE:SAIPARENT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.32 Med: 17.69 Max: 134.34
Current: 24.29
During the past 3 years, Sai Parenteral's's highest Return-on-Tangible-Equity was 134.34%. The lowest was 14.32%. And the median was 17.69%.
NSE:SAIPARENT's Return-on-Tangible-Equity is ranked better than 82.61% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.68
vs NSE:SAIPARENT: 24.29
Sai Parenteral's (NSE:SAIPARENT) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sai Parenteral's Return-on-Tangible-Equity Related Terms
Sai Parenteral's Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sai Parenteral's's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sai Parenteral's Return-on-Tangible-Equity Chart
Sai Parenteral's Annual Data
Trend
Mar23
Mar24
Mar25
Return-on-Tangible-Equity
14.32
17.69
134.34
Sai Parenteral's Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Return-on-Tangible-Equity
0.00
0.00
0.00
48.59
NSE:SAIPARENT vs LLY, JNJ, ABBV: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - General subindustry, Sai Parenteral's's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sai Parenteral's Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sai Parenteral's's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 48.59% mean?
Sai Parenteral's (NSE:SAIPARENT) has a Return-on-Tangible-Equity of 48.59% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sai Parenteral's and its competitors. This is 175% above median its historical median of 17.69. Over the past decade, Sai Parenteral's' Return-on-Tangible-Equity has ranged from 14.32 to 134.34. According to the industry distribution chart, Sai Parenteral's ranks #156 out of 897 companies in the Drug Manufacturers industry, placing it in the top 17.4%.
Is Sai Parenteral's' Return-on-Tangible-Equity too high?
Sai Parenteral's' current Return-on-Tangible-Equity of 48.59% is 175% above median its 10-year median of 17.69. Over the past 10 years, this metric has ranged from a low of 14.32 to a high of 134.34. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.68. Sai Parenteral's' value of 48.59% is 532.7% above this industry median. Based on the distribution chart, Sai Parenteral's ranks #156 out of 897 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Return-on-Tangible-Equity compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Sai Parenteral's ranks #156 out of 897 companies for Return-on-Tangible-Equity. This places Sai Parenteral's in the top 17% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.68. Sai Parenteral's' value of 48.59% is 532.7% above this benchmark. Historically, Sai Parenteral's' own Return-on-Tangible-Equity has ranged from 14.32 to 134.34 over the past decade. While the company's 10-year median is 17.69 vs. the industry median of 7.68, Sai Parenteral's has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.68, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sai Parenteral's's current Return-on-Tangible-Equity of 48.59% is 532.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sai Parenteral's and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sai Parenteral's's current Return-on-Tangible-Equity is 48.59%, which is 175% above median its own 10-year median of 17.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Return-on-Tangible-Equity of 48.59%. The current Return-on-Tangible-Equity is 48.59%, which is 175% above median its 10-year median of 17.69 and 532.7% above the Drug Manufacturers industry median of 7.68. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Return-on-Tangible-Equity is 48.59% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score
Get the complete analysis for NSE:SAIPARENT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAIPARENT has been successfully added to your 
